Glucagon-like peptide-1 (GLP-1) and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are highly effective therapies for overweight and obesity due to their potent ability to provide significant amounts of weight loss. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.